Prediction of O(6)-methylguanine-DNA Methyltransferase Promoter Methylation Status in IDH-wildtype Glioblastoma Using MRI Histogram Analysis

Overview

Journal Neurosurg Rev

Specialty Neurosurgery

Date 2024 Jun 21

PMID 38907038

Authors

Xianwang Liu

Tao Han

Yuzhu Wang

Hong Liu

Junlin Zhou

Affiliations

Soon will be listed here.

Abstract

To evaluate the utility of magnetic resonance imaging (MRI) histogram parameters in predicting O(6)-methylguanine-DNA methyltransferase promoter (pMGMT) methylation status in IDH-wildtype glioblastoma (GBM). From November 2021 to July 2023, forty-six IDH-wildtype GBM patients with known pMGMT methylation status (25 unmethylated and 21 methylated) were enrolled in this retrospective study. Conventional MRI signs (including location, across the midline, margin, necrosis/cystic changes, hemorrhage, and enhancement pattern) were assessed and recorded. Histogram parameters were extracted and calculated by Firevoxel software based on contrast-enhanced T1-weighted images (CET1). Differences and diagnostic performance of conventional MRI signs and histogram parameters between the pMGMT-unmethylated and pMGMT-methylated groups were analyzed and compared. No differences were observed in the conventional MRI signs between pMGMT-unmethylated and pMGMT-methylated groups (all p > 0.05). Compared with the pMGMT-methylated group, pMGMT-unmethylated showed a higher minimum, mean, Perc.01, Perc.05, Perc.10, Perc.25, Perc.50, and coefficient of variation (CV) (all p < 0.05). Among all significant CET1 histogram parameters, minimum achieved the best distinguishing performance, with an area under the curve of 0.836. CET1 histogram parameters could provide additional value in predicting pMGMT methylation status in patients with IDH-wildtype GBM, with minimum being the most promising parameter.

References

Chen X, Zhang M, Gan H, Wang H, Lee J, Fang D . A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018; 9(1):2949. PMC: 6063898. DOI: 10.1038/s41467-018-05373-4. View

Choi Y, Ahn S, Kim D, Chang J, Kang S, Kim E . Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. Radiology. 2016; 281(1):175-84. DOI: 10.1148/radiol.2016151913. View

Drabycz S, Roldan G, de Robles P, Adler D, McIntyre J, Magliocco A . An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2009; 49(2):1398-405. DOI: 10.1016/j.neuroimage.2009.09.049. View

Ellingson B, Cloughesy T, Pope W, Zaw T, Phillips H, Lalezari S . Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2011; 59(2):908-16. DOI: 10.1016/j.neuroimage.2011.09.076. View

Gihr G, Horvath-Rizea D, Kohlhof-Meinecke P, Ganslandt O, Henkes H, Richter C . Histogram Profiling of Postcontrast T1-Weighted MRI Gives Valuable Insights into Tumor Biology and Enables Prediction of Growth Kinetics and Prognosis in Meningiomas. Transl Oncol. 2018; 11(4):957-961. PMC: 6008484. DOI: 10.1016/j.tranon.2018.05.009. View

Han Y, Yan L, Wang X, Sun Y, Zhang X, Liu Z . Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer. 2018; 18(1):215. PMC: 5822523. DOI: 10.1186/s12885-018-4114-2. View

He W, Li X, Hua J, Liao S, Guo L, Xiao X . Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic.... J Magn Reson Imaging. 2021; 54(1):227-236. DOI: 10.1002/jmri.27514. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

10.

Liu X, Han T, Wang Y, Liu H, Huang X, Zhou J . Differentiating angiomatous meningioma from atypical meningioma using histogram analysis of apparent diffusion coefficient maps. Quant Imaging Med Surg. 2023; 13(7):4160-4170. PMC: 10347304. DOI: 10.21037/qims-22-1224. View

11.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

12.

Lu J, Li X, Li H . Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas. Magn Reson Imaging. 2021; 83:189-195. DOI: 10.1016/j.mri.2021.09.005. View

13.

Ostrom Q, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015; 17 Suppl 4:iv1-iv62. PMC: 4623240. DOI: 10.1093/neuonc/nov189. View

14.

Paz M, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L . CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004; 10(15):4933-8. DOI: 10.1158/1078-0432.CCR-04-0392. View

15.

Wang G, Zhou J . The value of whole-volume apparent diffusion coefficient histogram analysis in preoperatively distinguishing intracranial solitary fibrous tumor and transitional meningioma. Front Oncol. 2023; 13:1155162. PMC: 10228830. DOI: 10.3389/fonc.2023.1155162. View

16.

Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach J, Wick A . MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res. 2015; 21(9):2057-64. DOI: 10.1158/1078-0432.CCR-14-2737. View

17.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

18.

Xi Y, Guo F, Xu Z, Li C, Wei W, Tian P . Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging. 2017; 47(5):1380-1387. DOI: 10.1002/jmri.25860. View

19.

Xue C, Zhou Q, Zhang P, Zhang B, Sun Q, Li S . MRI histogram analysis of tumor-infiltrating CD8+ T cell levels in patients with glioblastoma. Neuroimage Clin. 2023; 37:103353. PMC: 9958466. DOI: 10.1016/j.nicl.2023.103353. View

20.

You S, Choi S, Kim T, Park C, Park S, Won J . Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging. Radiology. 2017; 286(3):981-991. DOI: 10.1148/radiol.2017170764. View